Vericel Corp VCEL
7 trading plans running, 36 Form 144 notices for $14.6M
10-Q, 10-K and Form 144What VCEL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From May 23, 2025 to Nov 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Dominick Colangelo Chief Executive Officer |
Adopted 10b5-1 plan | Aug 25, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn August 25, 2026, Dominick Colangelo, Vericel Corporation’s Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 279,307 shares of our common stock between December 9, 2026 and August 27, 2027. All of the shares subject to this arrangement are in the form of stock options that were awarded to Mr. Colangelo on February 7, 2018, and which would otherwise expire and become forfeitable on February 7, 2028. | |||||
| Kevin McLaughlin member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Aug 19, 2026 | 10-Q Nov 5, 2026 | ||
What the company wroteOn August 19, 2026, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 26,250 shares of our common stock between February 10, 2027 and November 30, 2027. | |||||
| Robert Zerbe Chairman of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | May 19, 2026 | 10-Q Jul 30, 2026 | ||
What the company wroteOn May 19, 2026, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 33,750 shares of our common stock between August 31, 2026 and September 30, 2027. | |||||
| Jonathan Siegal Principal Accounting Officer |
Adopted 10b5-1 plan | Dec 10, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 10, 2025, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 63,136 shares of our common stock between March 10, 2026 and November 6, 2026. | |||||
| Heidi Hagen member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Dec 4, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 4, 2025, Heidi Hagen, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,500 shares of our common stock between March 30, 2026, and May 28, 2027; and | |||||
| Joseph Mara Chief Financial Officer |
Adopted 10b5-1 plan | Dec 2, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 2, 2025, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 160,000 shares of our common stock between March 2, 2026, and March 5, 2027; and | |||||
| Michael Halpin Chief Operating Officer |
Adopted 10b5-1 plan | Dec 2, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 2, 2025, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 49,575 shares of our common stock between March 2, 2026, and February 26, 2027; and | |||||
| Sean Flynn Chief Legal Officer |
Adopted 10b5-1 plan | Dec 2, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteOn December 2, 2025, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 71,825 shares of our common stock between March 2, 2026 and November 6, 2026, and terminated a prior Rule 10b5-1 trading arrangement dated March 5, 2025; and | |||||
| Jonathan Hopper Chief Medical Officer |
Adopted 10b5-1 plan | May 30, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteOn May 30, 2025, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 37,847 shares of our common stock between September 2, 2025 and August 28, 2026. | |||||
| Robert Zerbe Chairman of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | May 23, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteOn May 23, 2025, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 7,500 shares of our common stock between September 2, 2025 and August 28, 2026; and | |||||
| Kevin McLaughlin member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | May 12, 2025 | 10-Q Jul 31, 2025 | ||
What the company wroteOn May 12, 2025, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between November 10, 2025 and November 30, 2026; | |||||
| Jonathan Siegal Principal Accounting Officer |
Adopted 10b5-1 plan | Mar 14, 2025 | 10-Q May 8, 2025 | ||
What the company wroteOn March 14, 2025, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 51,798 shares of our common stock between June 12, 2025 and February 27, 2026. | |||||
| Sean Flynn Chief Legal Officer |
Adopted 10b5-1 plan | Mar 5, 2025 | 10-Q May 8, 2025 | ||
What the company wroteOn March 5, 2025, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 41,825 shares of our common stock between June 5, 2025 and June 30, 2026; and | |||||
| Dominick Colangelo President and Chief Executive Officer |
Adopted 10b5-1 plan | Dec 2, 2024 | 10-K Feb 27, 2025 | ||
What the company wroteOn December 2, 2024, Dominick Colangelo, Vericel Corporation’s President and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 131,008 shares of our common stock between March 12, 2025, and June 2, 2025. | |||||
| Michael Halpin Chief Operating Officer |
Adopted 10b5-1 plan | Nov 19, 2024 | 10-K Feb 27, 2025 | ||
What the company wroteOn November 19, 2024, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 30,000 shares of our common stock between March 3, 2025, and February 27, 2026. | |||||
| Joseph Mara Chief Financial Officer |
Adopted 10b5-1 plan | Nov 15, 2024 | 10-K Feb 27, 2025 | ||
What the company wroteOn November 15, 2024, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement. Mr. Mara subsequently amended that trading arrangement on November 26, 2024. The amended trading arrangement provides for the potential sale of up to 88,500 shares of our common stock between March 3, 2025, and December 31, 2025. | |||||
| Heidi Hagen member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Nov 14, 2024 | 10-K Feb 27, 2025 | ||
What the company wroteOn November 14, 2024, Heidi Hagen, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 24,000 shares of our common stock between March 3, 2025, and March 27, 2026. | |||||
| Steven Gilman member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | May 30, 2024 | 10-Q Aug 1, 2024 | ||
What the company wroteOn May 30, 2024, Steven Gilman, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 22,500 shares of our common stock between September 4, 2024, and April 30, 2025. | |||||
| Jonathan Hopper Chief Medical Officer |
Adopted 10b5-1 plan | May 28, 2024 | 10-Q Aug 1, 2024 | ||
What the company wroteOn May 28, 2024, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 40,000 shares of our common stock between September 3, 2024 and August 29, 2025. | |||||
| Joseph Mara Chief Financial Officer |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn March 15, 2024, Joseph Mara, Vericel Corporation’s Chief Financial Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 5,000 shares of our common stock between June 13, 2024 and May 30, 2025. | |||||
| Jonathan Siegal Principal Accounting Officer |
Adopted 10b5-1 plan | Mar 13, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn March 13, 2024, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 42,577 shares of our common stock between June 13, 2024 and February 28, 2025; and | |||||
| Sean Flynn Chief Legal Officer |
Adopted 10b5-1 plan | Mar 13, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn March 13, 2024, Sean Flynn, Vericel Corporation’s Chief Legal Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 40,075 shares of our common stock between June 13, 2024 and May 30, 2025; | |||||
| Robert Zerbe Chairman of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Mar 12, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn March 12, 2024, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,500 shares of our common stock between September 3, 2024, and August 29, 2025; | |||||
| Kevin McLaughlin member of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Mar 11, 2024 | 10-Q May 8, 2024 | ||
What the company wroteOn March 11, 2024, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between August 7, 2024, and August 8, 2025; | |||||
| Jonathan Siegal Principal Accounting Officer |
Adopted 10b5-1 plan | Sep 14, 2023 | 10-Q Nov 8, 2023 | ||
What the company wroteOn September 14, 2023, Jonathan Siegal, Vericel Corporation’s Principal Accounting Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 23,800 shares of our common stock between December 13, 2023 and May 17, 2024. | |||||
| Dominick Colangelo President and Chief Executive Officer |
Adopted 10b5-1 plan | Sep 1, 2023 | 10-Q Nov 8, 2023 | ||
What the company wroteOn September 1, 2023, Dominick Colangelo, Vericel Corporation’s President and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 431,849 shares of our common stock between December 6, 2023 and December 31, 2024; and | |||||
| Michael Halpin Chief Operating Officer |
Adopted 10b5-1 plan | Aug 31, 2023 | 10-Q Nov 8, 2023 | ||
What the company wroteOn August 31, 2023, Michael Halpin, Vericel Corporation’s Chief Operating Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 32,834 shares of our common stock between November 30, 2023 and August 30, 2024; | |||||
| Jonathan Hopper Chief Medical Officer |
Adopted 10b5-1 plan | Aug 17, 2023 | 10-Q Nov 8, 2023 | ||
What the company wroteOn August 17, 2023, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 15,000 shares of our common stock between November 20, 2023 and October 31, 2024; | |||||
| Robert Zerbe Chairman of the Vericel Corporation Board of Directors |
Adopted 10b5-1 plan | Aug 11, 2023 | 10-Q Nov 8, 2023 | ||
What the company wroteOn August 11, 2023, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 17,000 shares of our common stock between November 15, 2023, and August 30, 2024; | |||||
Show the other 21 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 10, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 13, 2026 | SIEGAL JONATHAN Officer |
1,885 | $109K |
| Nov 12, 2026 | Mara Joseph Anthony Jr Officer |
8 | $478 |
| Nov 10, 2026 | MCLAUGHLIN KEVIN F Director |
7,000 | $409K |
| Nov 9, 2026 | ZERBE ROBERT L MD Director |
2,000 | $116K |
| Nov 9, 2026 | Mara Joseph Anthony Jr Officer |
25,000 | $1.5M |
| Nov 6, 2026 | Mara Joseph Anthony Jr Officer |
28,641 | $1.5M |
| Nov 6, 2026 | Mara Joseph Anthony Jr Officer |
28,641 | $1.5M |
| Nov 5, 2026 | Mara Joseph Anthony Jr Officer |
21,359 | $1.1M |
| Nov 5, 2026 | Flynn Sean C. Officer |
15,000 | $779K |
| Nov 5, 2026 | ZERBE ROBERT L MD Director |
3,000 | $157K |
| Nov 5, 2026 | SIEGAL JONATHAN Officer |
1,500 | $79K |
| Nov 4, 2026 | ZERBE ROBERT L MD Director |
2,500 | $114K |
| Aug 12, 2026 | MCLAUGHLIN KEVIN F Director |
7,000 | $309K |
| Aug 3, 2026 | Halpin Michael Officer |
10,000 | $460K |
| Jul 30, 2026 | SIEGAL JONATHAN Officer |
4,500 | $220K |
| Jun 26, 2026 | Flynn Sean C. Officer |
15,000 | $685K |
| Jun 26, 2026 | Mara Joseph Anthony Jr Officer |
5,000 | $224K |
| Jun 26, 2026 | SIEGAL JONATHAN Officer |
2,732 | $123K |
| Jun 26, 2026 | Hopper Jonathan Mark Officer |
10,000 | $450K |
| Jun 18, 2026 | Flynn Sean C. Officer |
15,000 | $603K |
| Jun 18, 2026 | Halpin Michael Officer |
10,000 | $402K |
| Jun 2, 2026 | Hopper Jonathan Mark Officer |
4,375 | $153K |
| May 13, 2026 | MCLAUGHLIN KEVIN F Director |
7,000 | $228K |
| May 11, 2026 | Wotton Paul K Director |
10,000 | $327K |
| May 7, 2026 | SIEGAL JONATHAN Officer |
1,422 | $58K |
| May 7, 2026 | Mara Joseph Anthony Jr Officer |
5,000 | $202K |
| May 6, 2026 | SIEGAL JONATHAN Officer |
3,433 | $130K |
| Apr 2, 2026 | Hopper Jonathan Mark Officer |
3,472 | $122K |
| Mar 23, 2026 | Hagen Heidi Director |
15,000 | $486K |
| Mar 2, 2026 | Flynn Sean C. Officer |
21,421 | $754K |
| Mar 2, 2026 | Halpin Michael Officer |
10,305 | $364K |
| Feb 11, 2026 | MCLAUGHLIN KEVIN F Director |
7,000 | $249K |
| Jan 7, 2026 | Halpin Michael Officer |
10,000 | $405K |
| Dec 3, 2025 | Wotton Paul K Director |
2,500 | $95K |
| Dec 2, 2025 | Hopper Jonathan Mark Officer |
1,652 | $65K |
| Dec 2, 2025 | Wotton Paul K Director |
2,500 | $95K |
Show the other 28 notices
From the Form 144 XML filed with the SEC, since Dec 2, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.